{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:14:29Z","timestamp":1788542069939,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01683-9","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:17:24Z","timestamp":1784737044000},"page":"1339-1351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low Tacrolimus C0\/Dose Ratio is Associated with Higher Cmax and AUC Despite Similar Pre-dose Concentrations"],"prefix":"10.1007","volume":"65","author":[{"given":"Amar D.","family":"Levens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Gelinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soufian","family":"Meziyerh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko P. J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"van der Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"3","key":"1683_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"key":"1683_CR2","doi-asserted-by":"crossref","unstructured":"KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl. 3):S1\u2013155.","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"issue":"10","key":"1683_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111128","volume":"9","author":"G Th\u00f6lking","year":"2014","unstructured":"Th\u00f6lking G, Fortmann C, Koch R, Gerth HU, Pabst D, Pavenst\u00e4dt H, et al. The tacrolimus metabolism rate influences renal function after kidney transplantation. PLoS ONE. 2014;9(10):e111128.","journal-title":"PLoS ONE"},{"issue":"6","key":"1683_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/TP.0000000000002920","volume":"104","author":"T Jouve","year":"2020","unstructured":"Jouve T, Fonrose X, Noble J, Janbon B, Fiard G, Malvezzi P, et al. The TOMATO study (Tacrolimus metabolization in kidney transplantation): impact of the concentration-dose ratio on death-censored graft survival. Transplantation. 2020;104(6):1263\u201371.","journal-title":"Transplantation"},{"key":"1683_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11027","volume":"36","author":"FA von Samson-Himmelstjerna","year":"2023","unstructured":"von Samson-Himmelstjerna FA, Messtorff ML, Kakavand N, Eisenberger U, Korth J, Lange U, et al. The tacrolimus concentration\/dose ratio does not predict early complications after kidney transplantation. Transpl Int. 2023;36:11027.","journal-title":"Transpl Int"},{"key":"1683_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12659\/AOT.895898","volume":"21","author":"G Th\u00f6lking","year":"2016","unstructured":"Th\u00f6lking G, Siats L, Fortmann C, Koch R, H\u00fcsing A, Cicinnati VR, et al. Tacrolimus concentration\/dose ratio is associated with renal function after liver transplantation. Ann Transplant. 2016;21:167\u201379.","journal-title":"Ann Transplant"},{"issue":"5","key":"1683_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/jcm8050587","volume":"8","author":"K Sch\u00fctte-N\u00fctgen","year":"2019","unstructured":"Sch\u00fctte-N\u00fctgen K, Th\u00f6lking G, Steinke J, Pavenst\u00e4dt H, Schmidt R, Suwelack B, et al. Fast Tac metabolizers at risk: it is time for a C\/D ratio calculation. J Clin Med. 2019;8(5):587.","journal-title":"J Clin Med"},{"key":"1683_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep32273","volume":"6","author":"G Th\u00f6lking","year":"2016","unstructured":"Th\u00f6lking G, Schmidt C, Koch R, Schuette-Nuetgen K, Pabst D, Wolters H, et al. Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep. 2016;6:32273.","journal-title":"Sci Rep"},{"issue":"4","key":"1683_CR9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cpt.70162","volume":"119","author":"AD Levens","year":"2026","unstructured":"Levens AD, Moes D, Boer Y, de Vries APJ, de Vries DK, van der Helm D, et al. Lower dose-normalized tacrolimus exposure in CYP3A5*6 vs. *3 loss-of-function allele carriers: a longitudinal retrospective real-world study in kidney transplant recipients. Clin Pharmacol Ther. 2026;119(4):942\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1683_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010017","volume":"16","author":"J Kamp","year":"2024","unstructured":"Kamp J, Zwart TC, Meziyerh S, van der Boog PJM, Nijgh EE, van Duin K, et al. Meltdose tacrolimus population pharmacokinetics and limited sampling strategy evaluation in elderly kidney transplant recipients. Pharmaceutics. 2024;16(1):17.","journal-title":"Pharmaceutics"},{"key":"1683_CR11","unstructured":"Dutch Medicines Evaluation Board (CBG). Public assessment report: Dailiport 0.5 mg, 1 mg, 2 mg, 3 mg and 5 mg, prolonged release hard capsules (tacrolimus monohydrate). 30 December 2019. Contract No.: NL\/H\/4508\/001-005\/DC."},{"key":"1683_CR12","unstructured":"Dutch Medicines Evaluation Board (CBG). Public assessment report: Adport 2 mg and 0.75 mg, capsules, hard (tacrolimus). 15 December 2014. Contract No.: NL\/H\/1340\/004-005\/DC."},{"issue":"6","key":"1683_CR13","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","volume":"67","author":"EM Scholten","year":"2005","unstructured":"Scholten EM, Cremers SCLM, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh JAN, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67(6):2440\u20137.","journal-title":"Kidney Int"},{"issue":"2","key":"1683_CR14","volume":"3","author":"DJ Moes","year":"2014","unstructured":"Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometr Syst Pharmacol. 2014;3(2):e100.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"1683_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","volume":"71","author":"JB Woillard","year":"2011","unstructured":"Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations: twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71(3):391\u2013402.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1683_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJ Moes","year":"2016","unstructured":"Moes DJ, van der Bent SA, Swen JJ, van der Straaten T, Inderson A, Olofsen E, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016;72(2):163\u201374.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1683_CR17","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1111\/bcp.13755","volume":"84","author":"TC Zwart","year":"2018","unstructured":"Zwart TC, Gokoel SRM, van der Boog PJM, de Fijter JW, Kweekel DM, Swen JJ, et al. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. Br J Clin Pharmacol. 2018;84(12):2889\u2013902.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1683_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101586","volume":"8","author":"G Th\u00f6lking","year":"2019","unstructured":"Th\u00f6lking G, Sch\u00fctte-N\u00fctgen K, Schmitz J, Rovas A, Dahmen M, Bautz J, et al. A low tacrolimus concentration\/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity. J Clin Med. 2019;8(10):1586.","journal-title":"J Clin Med"},{"issue":"10","key":"1683_CR19","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1016\/j.transproceed.2019.08.030","volume":"51","author":"E Kwiatkowska","year":"2019","unstructured":"Kwiatkowska E, Kwiatkowski S, Wahler F, Gryczman M, Doma\u0144ki L, Marchelk-My\u015bliwiec M, et al. C\/D ratio in long-term renal function. Transplant Proc. 2019;51(10):3265\u201370.","journal-title":"Transplant Proc"},{"issue":"8","key":"1683_CR20","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1097\/TP.0000000000001796","volume":"101","author":"EJ Egeland","year":"2017","unstructured":"Egeland EJ, Robertsen I, Hermann M, Midtvedt K, St\u00f8rset E, Gustavsen MT, et al. High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation. 2017;101(8):e273\u20139.","journal-title":"Transplantation"},{"issue":"3","key":"1683_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/tri.13356","volume":"32","author":"EJ Egeland","year":"2019","unstructured":"Egeland EJ, Reis\u00e6ter AV, Robertsen I, Midtvedt K, Str\u00f8m EH, Holdaas H, et al. High tacrolimus clearance: a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. Transplant Int. 2019;32(3):257\u201369.","journal-title":"Transplant Int"},{"key":"1683_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.phrs.2015.08.020","volume":"100","author":"F Saint-Marcoux","year":"2015","unstructured":"Saint-Marcoux F, Woillard JB, Monchaud C, Friedl J, Bocquentin F, Essig M, et al. How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. Pharmacol Res. 2015;100:281\u20137.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1683_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/ajt.13935","volume":"17","author":"S Tremblay","year":"2017","unstructured":"Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017;17(2):432\u201342.","journal-title":"Am J Transplant"},{"issue":"20","key":"1683_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206241","volume":"13","author":"A D\u0119bska-\u015alizie\u0144","year":"2024","unstructured":"D\u0119bska-\u015alizie\u0144 A, Ku\u017amiuk-Glembin I, Ho\u017cejowski R, Kami\u0144ska D, Krajewska M, Zawiasa-Bryszewska A, et al. Renal allograft function and the tacrolimus C\/D ratio: insights from a prospective study on MeltDose tacrolimus. J Clin Med. 2024;13(20):6241.","journal-title":"J Clin Med"},{"issue":"10","key":"1683_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/genes11101205","volume":"11","author":"T Gelder","year":"2020","unstructured":"Gelder T, Etsouli O, Moes DJ, Swen JJ. Comparison of the impact of pharmacogenetic variability on the PK of slow release and immediate release tacrolimus formulations. Genes (Basel). 2020;11(10):1205.","journal-title":"Genes (Basel)"},{"issue":"5","key":"1683_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051290","volume":"11","author":"G Th\u00f6lking","year":"2022","unstructured":"Th\u00f6lking G, Tosun-Ko\u00e7 F, Jehn U, Koch R, Pavenst\u00e4dt H, Suwelack B, et al. Improved kidney allograft function after early conversion of fast IR-Tac metabolizers to LCP-Tac. J Clin Med. 2022;11(5):1290.","journal-title":"J Clin Med"},{"issue":"11","key":"1683_CR27","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/bcp.15433","volume":"88","author":"TC Zwart","year":"2022","unstructured":"Zwart TC, Metscher E, van der Boog PJM, Swen JJ, de Fijter JW, Guchelaar HJ, et al. Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients. Br J Clin Pharmacol. 2022;88(11):4854\u201369.","journal-title":"Br J Clin Pharmacol"},{"key":"1683_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fphar.2020.01142","volume":"11","author":"T van Gelder","year":"2020","unstructured":"van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes D. The clinical impact of the C(0)\/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol. 2020;11:1142.","journal-title":"Front Pharmacol"},{"key":"1683_CR29","doi-asserted-by":"crossref","unstructured":"Kuypers DRJ, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Therapeutic Drug Monitoring. 2010;32(4):394\u2013404.","DOI":"10.1097\/FTD.0b013e3181e06818"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01683-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:09Z","timestamp":1788538989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01683-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the last 3 years, Teun van Gelder has received lecture fees and consulting fees from Roche Diagnostics, Thermo Fisher, Otsuka, CSL Behring, Astellas, and MaxyMune Therapeutics. In all cases, money has been transferred to hospital accounts, and none has been paid to his personal bank accounts. Teun van Gelder does not have employment or stock ownership at any of these companies, and neither does he have patents or patent applications. Jesse J. Swen received speaker fees from Lundbeck paid directly to his employer (Leiden University Medical Center). Soufian Meziyerh received speaker fees from Chiesi, paid directly to his employer (Leiden University Medical Center). Aiko P.J. de Vries received lecture and consulting fees from Hansa, Sanofi, Takeda, Memo, and Vunthera; all paid directly to his employer (Leiden University Medical Center). Teun van Gelder and Dirk Jan A.R. Moes are Editorial Board members of\n                      Clinical Pharmacokinetics\n                      . They were not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Amar D. Levens, Armin Gelinck, and Danny van der Helm have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Review Committee Leiden Den Haag Delft (METC LDD) reviewed the study protocol and confirmed that it does not fall under the scope of the Medical Research Involving Human Subjects Act (WMO). Therefore, obtaining written informed consent was not required (nWMO-D4-2025-005).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As confirmed by the Medical Ethics Review Committee Leiden Den Haag Delft (METC LDD), this study did not fall under the scope of the Dutch Medical Research Involving Human Subjects Act (WMO), and written informed consent was therefore not required (reference: nWMO-D4-2025-005). All kidneys used for transplantation were obtained through the Leiden Transplant Center, Leiden University Medical Center. No organs or tissues were obtained from prisoners.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses underlying the conclusions are described in the article and its supplementary materials. Owing to institutional and ethical restrictions, the datasets generated and\/or analyzed in this study are not publicly available; de-identified datasets and the analysis can be obtained from the corresponding author on reasonable request. Scripts were developed in a Dutch clinical context and contain both Dutch and English language elements, reflecting the original data structure.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: TVG, DJARM, and ADL; acquisition of data: DvdH and ADL; formal analysis and visualization: ADL, DJARM, and TVG; methodology and validation: ADL, DJARM, AdV, SM, AG, JJS, and TVG; project administration: ADL; supervision: DJARM and TVG; writing (original draft): ADL and TVG; writing (review and editing): ADL, DJARM, JJS, SM, AG, TVG, DvdH, and AdV. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}